AstraZeneca Groomed Paul Hudson For His New Role … At Novartis
Executive Summary
Ten years at AstraZeneca PLC have prepared US President and Executive Vice President of North America Paul Hudson for his next C-suite job, but unfortunately for his current employer that gig is with a major competitor – Novartis AG.
You may also be interested in...
Novartis Pharma CEO Paul Hudson Discusses Leadership And Launches
Hudson has gained his footing running Novartis' pharma business. Now, he's preparing to launch seven new drugs by 2020 while growing Cosentyx, Entresto and other in-line products.
2Q Pharma Results Preview: What Lies Ahead
The big pharma financial reporting season gets underway on July 19 with Novartis and Johnson & Johnson in the vanguard. Biosimilar threats to immunology and cancer drugs and new product ramp-ups are among the key things to watch for as results are announced.
Panel: Pricing Dilemma Divides Industry Stakeholders
Drug pricing has become the most contentious issue in the pharma world over the last two years as politics has dragged the subject into the mainstream conversation. Yet, even those within the industry have different ideas on how the problem can be fixed.